Showing results (11-20 of 148) with videos related to

Sort By:
Pageof 15
International Journal of Clinical Oncology|August 19, 2007
Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactionsShinji Sasada, Tomonori Hirashima, Yukiko Nakamura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 12, 2005
Gefitinib for previously untreated patients with non-small cell lung cancer (NSCLC)--a retrospective study of 12 patients treated in one institutionTakayuki Takimoto, Tomonori Hirashima, Masashi Kobayashi, et al.
Medical Oncology (Northwood, London, England)|January 25, 2011
Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancerMotohiro Tamiya, Hidekazu Suzuki, Masashi Kobayashi, et al.
Journal of Thoracic Disease|February 24, 2016
Chemotherapy for patients with advanced lung cancer receiving long-term oxygen therapyManabu Hayama, Hidekazu Suzuki, Takayuki Shiroyama, et al.
Asia-Pacific Journal of Clinical Oncology|December 23, 2016
Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapyMotohiro Tamiya, Takayuki Shiroyama, Takashi Nishihara, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 1, 2012
Serum HE4 as a diagnostic and prognostic marker for lung cancerKota Iwahori, Hidekazu Suzuki, Yoshiro Kishi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 15, 2002
Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecanJunji Tsurutani, Takashi Nitta, Tomonori Hirashima, et al.
Chinese Journal of Cancer|December 15, 2012
The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutationsHidekazu Suzuki, Tomonori Hirashima, Norio Okamoto, et al.
Investigational New Drugs|June 17, 2020
Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective studyShingo Nasu, Hidekazu Suzuki, Takayuki Shiroyama, et al.
International Journal of Clinical Oncology|August 29, 2006
Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancerMasashi Kobayashi, Kaoru Matsui, Tomonori Hirashima, et al.
Pageof 15